

Attorney Docket No.: 5698.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Commissioner for Patents Washington, DC 20231

Express Mail Label No. EL 049071824US Date of Deposit February 8, 2002

Sir:

This is a request for filing a divisional application under 37 C.F.R. 1.53(b) of

Applicant(s): Jeppesen et al.

Title: Substituted Hetero-Polycyclic Compounds as PPARα and PPARγ

Activators (As Amended)

65 pages of specification 1 page of abstract

- 0 sheets of Formal Drawings
- 2 sheets of Executed Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee:

\$740.00

Total Claims: $10 - 20 = 0 \times 18 =$ \$0

Independent Claims: $1 - 3 = 0 \times 84 =$

\$0

Total Fee:

\$740.00

Priority of Danish application no. PA 1998 01352 filed on October 21, 1998 is claimed under 35 U.S.C. 119. A certified copy was submitted with parent application no. 09/419,761 filed on October 19, 1999.

Priority of U.S. provisional application no. 60/105,912 filed on October 28, 1998 is -claimed under 35 U.S.C. 119.

The benefit of application no. 09/419,761 filed on October 19, 1999 in the U.S. is claimed under 35 U.S.C. 120.



Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$740, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: February 8, 2002

Peter J. Waibel, Reg. No. 43,228 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401 (212) 867-0123

Respectfully submitted,

PATENT TRADEMARK OFFICE

Attorney Docket No.: 5698.210-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application Commissioner for Patents 2900 Crystal Drive Arlington, VA 22202-3513

Re: U.S. Patent Application for

Title: Substituted Hetero-Polycyclic Compounds as PPAR α and PPAR γ

Activators (As Amended)

Sir:

Express Mail Label No. EL 049071824US

Date of Deposit: February 8, 2002

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Copy of Executed Combined Declaration and Power of Attorney
- 4. Preliminary Amendment
- 5. Information Disclosure Statement
- 6. Form PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, 2900 Crystal Drive, Arlington, VA 22202-3513.

Carol McFarlane-Fishberg

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123

23650
PATENT TRADEMARK OFFICE